PA
AGRX

Pinnacle Associates’s Agile Therapeutics AGRX Stock Holding History

Pinnacle Associates’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10
Closed -$50K – 743
2019
Q4 		$50K Buy
+10
New +$34.9K ﹤0.01% 707
2017
Q2 		– Sell
-5
Closed -$32K – 694
2017
Q1 		$32K Hold
5
– – ﹤0.01% 654
2016
Q4 		$57K Sell
5
-20
-80% -$280K ﹤0.01% 630
2016
Q3 		$350K Sell
25
-13
-34% -$186K 0.01% 521
2016
Q2 		$572K Sell
38
-1
-3% -$13.7K 0.01% 450
2016
Q1 		$484K Buy
39
+15
+63% +$194K 0.01% 461
2015
Q4 		$471K Sell
24
-1
-4% -$15.8K 0.01% 468
2015
Q3 		$334K Hold
25
– – 0.01% 506
2015
Q2 		$426K Hold
25
– – 0.01% 487
2015
Q1 		$460K Buy
+25
New +$438K 0.01% 470

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pinnacle Associates's AGRX Position: Q1 2020 in Review

Pinnacle Associates sold out of Agile Therapeutics (AGRX) in Q1 2020, closing a stake of 10 shares — an estimated $50K sold.

Pinnacle Associates first reported a position in AGRX in Q1 2015 and held it in 10 quarters. The position peaked at $572K in Q2 2016. 61 funds tracked by Wall St. Rank hold AGRX as of Q1 2020.

  • Pinnacle Associates reported no remaining Agile Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Pinnacle Associates sold 10 Agile Therapeutics shares in Q1 2020, an estimated $50K.
  • Pinnacle Associates first reported a position in Agile Therapeutics in Q1 2015 and held it in 10 quarters.
  • Pinnacle Associates's Agile Therapeutics position peaked at $572K in Q2 2016.
  • 61 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2020.

Based on Pinnacle Associates's 13F filing for Q1 2020, filed 13 May 2020.